170 related articles for article (PubMed ID: 9145825)
21. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
Rice LB; Carias LL; Shlaes DM
Antimicrob Agents Chemother; 1994 Nov; 38(11):2663-4. PubMed ID: 7872765
[TBL] [Abstract][Full Text] [Related]
22. In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Nomura S; Hanaki H; Unemi N
Chemotherapy; 1996; 42(4):253-8. PubMed ID: 8804792
[TBL] [Abstract][Full Text] [Related]
23. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
WaKabongo M; Stucki ZN; Torbert DP; Olweny J
J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
[No Abstract] [Full Text] [Related]
24. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Leonard SN
PLoS One; 2012; 7(7):e42103. PubMed ID: 22848719
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial activity of penicillins alone and in combination with different agents against Staphylococcus aureus.
Nosheen S; Ejaz H; Zafar A; Ikram H
Pak J Pharm Sci; 2017 Mar; 30(2):393-397. PubMed ID: 28649062
[TBL] [Abstract][Full Text] [Related]
27. In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus.
Kazmierczak A; Duez JM; Pechinot A; Nordmann P; Labia R
Rev Infect Dis; 1986; 8 Suppl 5():S549-54. PubMed ID: 3026003
[TBL] [Abstract][Full Text] [Related]
28. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Falagas ME; McDermott L; Snydman DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
[TBL] [Abstract][Full Text] [Related]
29. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
[TBL] [Abstract][Full Text] [Related]
30. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
31. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Hyatt JM; Nix DE; Stratton CW; Schentag JJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
[TBL] [Abstract][Full Text] [Related]
32. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.
Kang SL; Rybak MJ
Antimicrob Agents Chemother; 1995 Jul; 39(7):1505-11. PubMed ID: 7492094
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
35. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Castagnola E; Bandettini R; Ginocchio F; Perotti M; Masa DL; Ciucci A; Loy A; Caviglia I; Haupt R; Guida E; Pini Prato A; Mattioli G; Buffa P
J Chemother; 2013 Aug; 25(4):213-6. PubMed ID: 23906074
[TBL] [Abstract][Full Text] [Related]
37. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species.
Climo MW; Markowitz SM; Williams DS; Hale-Cooper CG; Archer GL
J Antimicrob Chemother; 1997 Jul; 40(1):59-66. PubMed ID: 9249205
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of sulbactam/ampicillin and ampicillin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Fabbri A; Tacchella A; Belli ML; Losurdo G
Chemioterapia; 1988 Oct; 7(5):306-8. PubMed ID: 3224398
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
